|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM207374015 |
003 |
DE-627 |
005 |
20231224001935.0 |
007 |
cr uuu---uuuuu |
008 |
231224s2011 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1016/j.clim.2011.03.015
|2 doi
|
028 |
5 |
2 |
|a pubmed24n0691.xml
|
035 |
|
|
|a (DE-627)NLM207374015
|
035 |
|
|
|a (NLM)21482483
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Rappl, Gunter
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation
|
264 |
|
1 |
|c 2011
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 11.08.2011
|
500 |
|
|
|a Date Revised 17.03.2022
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Copyright © 2011 Elsevier Inc. All rights reserved.
|
520 |
|
|
|a Sarcoidosis can evolve into a chronic disease with persistent granulomas accompanied by progressive fibrosis. While an unlimited inflammatory response suggests an impaired immune control in sarcoid lesions, it stands in contrast to the massive infiltration with CD4(+)CD25(high)FoxP3(+) regulatory T cells. We here revealed that those Treg cells in affected lung lesions were mainly derived from activated natural Treg cells with GARP (LRRC32)-positive phenotype but exhibited reduced repressor capacities despite high IL-10 and TGF-beta 1 levels. The repressive capacity of blood Treg cells, in contrast, was not impaired compared to age-matched healthy donors. Treg derived cells in granuloma lesions have undergone extensive rounds of amplifications indicated by shortened telomeres compared to blood Treg cells of the same patient. Lesional Treg derived cells moreover secreted pro-inflammatory cytokines including IL-4 which sustains granuloma formation through fibroblast amplification and the activation of mast cells, the latter indicated by the expression of membrane-bound oncostatin M
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
700 |
1 |
|
|a Pabst, Stefan
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Riemann, Dagmar
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Schmidt, Annette
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Wickenhauser, Claudia
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Schütte, Wolfgang
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Hombach, Andreas A
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Seliger, Barbara
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Grohé, Christian
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Abken, Hinrich
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 140(2011), 1 vom: 01. Juli, Seite 71-83
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
773 |
1 |
8 |
|g volume:140
|g year:2011
|g number:1
|g day:01
|g month:07
|g pages:71-83
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2011.03.015
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 140
|j 2011
|e 1
|b 01
|c 07
|h 71-83
|